Eleni Zuppas - Veeva Systems Chief Officer
| VEE Stock | EUR 212.70 0.70 0.33% |
Insider
Eleni Zuppas is Chief Officer of Veeva Systems
| Age | 53 |
| Phone | 925 452 6500 |
| Web | https://www.veeva.com |
Eleni Zuppas Latest Insider Activity
Tracking and analyzing the buying and selling activities of Eleni Zuppas against Veeva Systems stock is an integral part of due diligence when investing in Veeva Systems. Eleni Zuppas insider activity provides valuable insight into whether Veeva Systems is net buyers or sellers over its current business cycle. Note, Veeva Systems insiders must abide by specific rules, including filing SEC forms every time they buy or sell Veeva Systems'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Eleni Zuppas over a year ago Exercise or conversion by Eleni Zuppas of 1620 shares of Veeva Systems subject to Rule 16b-3 | ||
Eleni Zuppas over a year ago Exercise or conversion by Eleni Zuppas of 1620 shares of Veeva Systems subject to Rule 16b-3 | ||
Eleni Zuppas over a year ago Acquisition by Eleni Zuppas of 25916 shares of Veeva Systems subject to Rule 16b-3 |
Veeva Systems Management Efficiency
The company has return on total asset (ROA) of 0.0778 % which means that it generated a profit of $0.0778 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1281 %, meaning that it generated $0.1281 on every $100 dollars invested by stockholders. Veeva Systems' management efficiency ratios could be used to measure how well Veeva Systems manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Christopher Caridi | Teladoc | 53 | |
| Jean Philibert | 10X GENOMICS DL | 59 | |
| Shehnaaz Suliman | 10X GENOMICS DL | 47 | |
| Hemant Taneja | Teladoc | 44 | |
| Bradford Crutchfield | 10X GENOMICS DL | 56 | |
| Eric Whitaker | 10X GENOMICS DL | 52 | |
| Sandra Fenwick | Teladoc | 68 | |
| Dan McCarthy | Evolent Health | N/A | |
| Emanuele Mugnani | Compugroup Medical SE | 53 | |
| Claudia Thom | Compugroup Medical SE | 52 | |
| George Brooks | Teladoc | N/A | |
| Eckart Pech | Compugroup Medical SE | 54 | |
| Kali Beyah | Evolent Health | N/A | |
| Helge Wei | Compugroup Medical SE | N/A | |
| MBA LLM | Compugroup Medical SE | 51 | |
| Michelle Bucaria | Teladoc | 48 | |
| Michael Franz | Compugroup Medical SE | N/A | |
| Benjamin Hindson | 10X GENOMICS DL | 44 | |
| Alexander Weimer | Compugroup Medical SE | N/A | |
| CPA CFA | Teladoc | N/A | |
| Courtney McLeod | Teladoc | N/A | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0778 |
Veeva Systems Leadership Team
Elected by the shareholders, the Veeva Systems' board of directors comprises two types of representatives: Veeva Systems inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veeva. The board's role is to monitor Veeva Systems' management team and ensure that shareholders' interests are well served. Veeva Systems' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veeva Systems' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Gassner, CEO, Founder, Director | ||
| Ato Garrett, Director Relations | ||
| Michele OConnor, Principal Accounting Officer | ||
| Jonathan Faddis, Senior Vice President General Counsel, Corporate Secretary | ||
| Alan Mateo, Executive Vice President of Sales | ||
| Pinal Patel, Chief Officer | ||
| Jacques Mourrain, VP Compliance | ||
| Brent Bowman, Chief Officer | ||
| Eleni Zuppas, Chief Officer | ||
| Thomas Schwenger, Pres COO |
Veeva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veeva Systems a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0778 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 22.59 B | |||
| Shares Outstanding | 140.92 M | |||
| Shares Owned By Insiders | 0.73 % | |||
| Shares Owned By Institutions | 94.21 % | |||
| Price To Earning | 86.56 X | |||
| Price To Book | 7.89 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Veeva Stock
Veeva Systems financial ratios help investors to determine whether Veeva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Veeva with respect to the benefits of owning Veeva Systems security.